Sugi Predict

Sugi Predict / Compounds / SCHEMBL19709331

SCHEMBL19709331

SCHEMBL19709331

COc1cc(F)ccc1N1CCNC[C@@H]1C

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 13/20 0.47
▸ HTR2B P41595 11/20 0.47
▸ BRPF1 P55201 3/20 0.46
▸ BRD1 O95696 2/20 0.46
▸ BRD4 O60885 1/20 0.46
▸ BRPF3 Q9ULD4 1/20 0.46
▸ HTR2A P28223 7/20 0.44
▸ KCNH2 Q12809 1/20 0.42
▸ RAD52 P43351 1/20 0.42
▸ CCNT1 O60563 2/20 0.41
▸ CDK9 P50750 2/20 0.41
▸ DRD2 P14416 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ HTR6 P50406 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21359240 1.00 HTR2C (0.47) HTR2CHTR2BBRPF1BRD1BRD4
SCHEMBL21359242 1.00 HTR2C (0.47) HTR2CHTR2BBRPF1BRD1BRD4
SCHEMBL30952461 1.00 HTR2C (0.47) HTR2CHTR2BBRPF1BRD1BRD4
SCHEMBL22542060 0.85 BRPF1 (0.47) HTR2CHTR2BBRPF1BRD1BRD4
SCHEMBL22542057 0.85 BRPF1 (0.47) HTR2CHTR2BBRPF1BRD1BRD4
SCHEMBL19709395 0.84 HTR3E (0.51) HTR2CHTR2BBRPF1BRD1BRD4
SCHEMBL4196575 0.84 NR4A1 (0.46) HTR2CHTR2BBRPF1BRD1BRD4
SCHEMBL19709315 0.83 HTR2C (0.44) HTR2CHTR2BBRPF1BRD1BRD4
SCHEMBL25407437 0.83 DRD2 (0.58) HTR2CHTR2BBRPF1BRD1BRD4
SCHEMBL26288599 0.83 DRD2 (0.58) HTR2CHTR2BBRPF1BRD1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10829478-B2 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis GALAPAGOS NV (BE) 2020-11-10 — — US disclosed
US-10829478-B2 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis GALAPAGOS NV (BE) 2020-11-10 — — US disclosed
US-20190315719-A1 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS GALAPAGOS NV (BE) 2019-10-17 — — US disclosed
US-20190315719-A1 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS GALAPAGOS NV (BE) 2019-10-17 — — US disclosed
WO-2017211666-A1 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS GALAPAGOS NV (BE) 2017-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315719-A1 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS ADAMTS5, ADAMTS4, ADAMTS1 HTR2C 980/4885HTR2B 312/4885BRPF1 3160/4885
US-10829478-B2 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis ADAMTS5, ADAMTS4, ADAMTS1 HTR2C 980/4885HTR2B 312/4885BRPF1 3160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.